



Inhalation
2. Respiratory
Drug Delivery |
Connected Devices

- Digital trends in drug delivery for lungs
- Eco-friendly inhalers for a sustainable future
- Achieving sustainability goals in medical devices...

### JOIN US .

World of Wine, Rua do Choupelo 39 Porto, Portugal

## **SPONSORED BY**

DIAMOND



**GOLD** 







WE ARE MICRONIZATION

**SILVER** 





### **MEDIA PARTNERS**

















• • • •

**RESCON EUROPE** highlights innovations in the respiratory sector and connected devices. RESCON EUROPE will feature key case studies on the latest trends in Sustainable Inhalation devices, Inhaled mRNA Therapy, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis. Further discussion focusses at on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices.

### **LEARN**

### THE KEY PRACTICAL POINTS



- Digital trends in lung drug delivery
- Green inhalers and sustainability in devices
- Plastic supplier insights on sustainability
- Combined nasal and pulmonary vaccine delivery
- User factors affecting dry powder inhalers
- Alternative pathway for generic respiratory products
- Biopharmaceutical modeling from in vitro to PK
- Preclinical studies on intranasal medication delivery
- Advances in nebulizer technology for respiratory drug delivery
- Novel approaches to treating asthma and COPD
- Regulatory considerations for inhaled drug products and connected devices.
- Optimizing drug delivery with high flow nasal cannula
- Liquid foams for high-dose pulmonary therapy

- Risk of nebulizer treatment in infection transmission
- Aerosol delivery for interstitial lung disease
- Inhaled divalent salts for respiratory illness treatment
- Microbiota modulation for cough treatment
- Analytical tools for inhaled medicines

. . . . . . . . . .


. . . . . . . . . . .

- Challenges and opportunities in developing inhaled biologics
- Impact of COVID-19 on inhalation drug delivery & respiratory care
- Post-market surveillance data and inhalation product development

SPEAKERS SPEAKERS.



Director, Medicinal Chemistry at AstraZeneca



Associate Professor at the Food and Drug Department, University of Parma (IT)



Director Sales and
Business Development
at Global Inhalation
& Medical Devices –
Berry Healthcare



Director Core
Facility Imaging,
Center for Medical
Research at Medical
University of Graz



Vice-president of Associação Nacional de Fibrose Quística (ANFQ)



Professor &
Associate Dean for
Research at Texas
State University



CEO at VisionHealth
GmbH



Senior Adviser -Inhalation Science at Emmace Consulting AB



Sr. Marketing
Manager HealthCare
Global at Avient
Colorants Germany
GmbH



Leader-Formulation and Drug Delivery at Research Center Pharmaceutical Engineering GmbH (RCPE)



CEO at *Fluidda* 



Associate Professor
of Biomedical
Engineering at
Technion - Israel
Institute of
Technology



Managing Human
Factors Specialist at
Emergo by UL



Physician at Tel Aviv Medical Center



Professor in
Pharmaceutics and
Biopharmaceutics
at *Trinity College*Dublin



Inventor and independent researcher



CEO of Emmace
Consulting



Professor Emerita at the Johns Hopkins School of Medicine



Vice President of Regulatory & Quality at *PAVmed Inc.* 




nnovation Scout at Boehringer Ingelheim Pharma




Senior Human
Factors Engineer at
Roche




CTO & Founder at



Senior Sales Manager at *Harro Höfliger* 



Founder at *FEND* 



# SCIENTIFIC

AGENDA.

## JUNE 19TH, MON

#### 18:00 - 19:00

Planet Cork Networking Experience

#### 19:00 - 20:00

Pre-Conference Cocktail Reception



## **JUNE 20TH, TUE**

### 08:00 - 08:20

Registration & Welcome Coffee

#### 08:20 - 08:30

**RESCON Europe Opening Speech** 

By Joana Roque Vice-president of Associação Nacional de Fibrose Quística (ANFQ)

Patients as Partners in Research & Development.

- » The value of integrating patient experience and perspective since early stages of R&D.
- » The Cystic Fibrosis experience in Europe.

### 08:30 - 09:00

Emerging digital trends in drug delivery to the lungs

By Sabine Häussermann CEO at VisionHealth GmbH

- » Enhanced drug delivery.
- » Market challenges in digitalisation strategies.

### 09:00 - 09:30

Grey Soft Mist Inhalers for a green environment

By Herbert Wachtel Innovation Scout at Boehringer Ingelheim Pharma

- » Design features of a re-usable Inhaler:
- > Multi-Dose cartridge
- Multi-cartridge device
- » Performance characteristics:
- > Slowly moving soft mist with long spray duration
- > Delivered Dose
- > Aerodynamic Particle Size Distribution
- » The carbon footprint of Respimat SMI:
- > Investigation of the life cycle from cradle to grave.

#### 09:30 - 10:00

How to achieve your sustainability goals in Medical Devices. Insights from a plastic material suplier perspective.

By Volker Dickfeld Sr. Marketing Manager HealthCare Global at Avient Colorants Germany GmbH

- » In this presentation we will highlight, new material options to reduce the carbon footprint for healthcare application, while keeping the regulatory integrity.
- » Learn more, on how to reduce the carbon footprint using color and additive solutions formulated with bio-based polymers. You will get insides on the concrete PCF Product carbon footprint savings of these solutions, that are of cause specially designed for the use in regulated healthcare applications with regulatory compliance support and comprehensive documentation.
- » In addition, you will discover further option to save material, reducing weight of plastic article, using special Additive solutions.

#### 10:00 - 10:20

Speed Networking

#### 10:20 - 11:00

Morning Coffee Break & Sponsors Presentation

#### 11:00 - 11:30

Novel system for combined nasal and pulmonary drug delivery of vaccines By **Orest Lastow** CTO & Founder at Iconovo AB

- » Future pandemics are expected to be caused by airborne virus infecting the respiratory tract. Several studies have shown that Mucosal IgA can provide immunity against respiratory viruses. A future vaccine, treatment or prophylactic drug could therefore be more efficacious using combined nasal and pulmonary delivery to give maximal mucosal absorption in the entire respiratory tract.
- » A non-invasive method to simultaneously administer drug or vaccine to both the nose and the lung could be an important first line of defense against the next pandemic. Several nasal spray vaccines are under development, but sprays have the inherent limitation in terms of short shelf-life and coordination issues. A passive dry powder delivery system would address the limitation of wet sprays. A nasal DPI is driven by the inspiratory flow, eliminating all coordination issues. A dry powder is stable in room temperature eliminating the need for expensive and complicated cold storage. The dry powder formulation can also be optimized to give a maximal pulmonary deposition.
- » A platform for simple and cost-efficient delivery of vaccines and biomolecules via the nose has been developed and optimized. The dry powder inhalation platform includes a device and a family of dry powder formulations. The platform is developed to be ultra-low-cost and suitable for low-income countries and tropical conditions. The project is funded by Bill & Melinda Gates Foundation.

#### 11:30 - 12:00

Aiming to the balance point: thinking next generation DPIs

By **Marco Franza** Director Sales and Business Development at Global Inhalation & Medical Devices – Berry Healthcare

- » Digital empowerment;
- » Different approaches for sustainable development of generic DPI.

#### 12:00 - 12:30

Patient in-use factors decisive to the performance of dry powder inhalers

By Amrit Paudel Leader-Formulation and Drug Delivery at Research Center Pharmaceutical

Engineering GmbH (RCPE)

#### 12:30 - 13:00

Challanges of powder dosing in inhalation product manufacturing

By Marian Asch Senior Sales Manager at Harro Höfliger

- » Powder properties and its impact on manufacturing processes;
- Considerations from lab to production during the development of Dry Powder Inhaler products;
- » Two-stage filling for pMDI manufacturing.

#### 13:00 - 14:00

**Business Lunch** 

#### 14:00 - 14:30

Physiology Based Biopharmaceutical Modeling - Bridging from In Vitro to PK By **Per Bäckman** Senior Adviser - Inhalation Science at Emmace Consulting AB

- » The potential of PBBM modelling to understand and predict the pharmacokinetics of inhaled medicines will be discussed. This will include predictions of PK parameters such as AUC and Cmax based on critical product attributes such as dissolution, dose deposition and delivered dose in support of pivotal bioequvalence studies.
- » From a biopharmaceutical standpoint, critical product and drug attributes describe the extent to which the dose reaches the lung, dose penetration into the distal parts of the lung, dissolution rate in situ, permeation through lung epithelium and diffusion through lung tissue into the systemic circulation
- » PBBM models mechanistically describe the processes involved and allow for the prediction of systemic and local exposure following administration of an inhaled medicine. This provide opportunities to predict bioequivalence between products, define clinically relevant product design specifications, as well as the potential of novel and repurposed drugs for inhalation.



Filling trials • Powder blending • DPI analytic (emitted dose, fine particle dose) • Technical sample manufacturing • Stabilities

#### 14:30 - 15:00

Preclinical studies of factors that affect delivery of aerosolized medications within the intranasal airways using 3D models

By Beth Laube Professor Emerita at the Johns Hopkins School of Medicine

#### 15:00 - 15:30

Optimizing Aerosol Drug Delivery via High Flow Nasal Cannula

By Arzu Ari Professor & Associate Dean for Research at Texas State University

- » Overview of transnasal aerosol delivery via high flow nasal cannula (HFNC) application and its safety.
- » Present the latest research on aerosol delivery via HFNC
- » Provide strategies to optimize aerosol delivery during HFNC based on the best evidence

#### 15:30 - 16:00

Liquid Foams for efficient delivery of high-dose pulmonary therapies

By **Josué Sznitman** Associate Professor of Biomedical Engineering at Technion - Israel Institute of Technology

#### 16:00 - 16:30

Afternoon Coffee Break & Sponsors Presentation

#### 16:30 - 17:00

The risk of nebulizer treatments in the transmission of bacteria and viruses - A Systematic Review

By Israel Amirav Physician at Tel Aviv Medical Center

#### 17:00 - 17:30

Panel Discussion: "The Future of Inhalation Therapy: Innovations and Challenges"

- » Emerging technologies and innovations in inhalation therapy
- » Challenges in developing inhalation therapy for different respiratory conditions
- » Regulatory considerations for inhalation therapy products
- » Patient-centered approach in inhalation therapy development
- » Sustainability and environmental impact of inhalation therapy devices
- » The role of digital health in improving inhalation therapy outcomes

#### 17:30 - 17:35

RESCON Europe 1st Day Closing Remarks

#### 19:00 - 20:00

**Networking Wine Experience** 

#### 20:00 - 22:00

Gala Dinner With Live Fado Concert

### **JUNE 2IST. WED**

#### 08:00 - 08:20

Registration & Welcome Coffee

#### 08:30 - 09:00

Aerosol delivery in ILD - breakthrough or lost cause?

By Carsten Ehrhardt Professor in Pharmaceutics and Biopharmaceutics at Trinity College Dublin

- » Interstitial lung disease (ILD) is an umbrella term used for a large group of diseases that cause irreversible fibrosis of the lungs. In many cases, such as idiopathic pulmonary fibrosis (IPF), the causes may be unknown.
- » There is currently no cure for IPF. Pirfenidone and nintedanib are used with the aim of relieving the symptoms as much as possible and slowing down its progression. Bot drugs, however, cause significant unwanted side effects when given orally.
- » Inhalation therapy could potentially increase the local drug concentration while simultaneously decrease systemic exposure. This presentation will explore if it is possible and meaningful to deliver drug aerosols to fibrotic lungs.

#### 09:00 - 09:30

Replacement Strategies for Animal Studies in Inhalation Testing

By **Eleonore Fröhlich** Director Core Facility Imaging, Center for Medical Research at Medical University of Graz

#### 09:30 - 10:00

Nasally Inhaled Divalent Salts for Prophylaxis and Treatment of Upper Respiratory Illnesses such as Chronic Cough

By David Edwards Founder at FEND

#### 10:00 - 10:30

Treatment for cough or lactobacilli powders for microbiota modulation

By Francesca Buttini Associate Professor at the Food and Drug Department, University of Parma (IT)

#### 10:30 - 11:00

Morning Coffee Break & Sponsors Presentation

#### 11:00 - 11:30

Analytical tools for inhaled medicines

By Mårten Svensson CEO at Emmace Consulting

- » Analytical insights into dry powder formulations for inhalation.
- » Characterizing aerosol dynamics
- » Tests according to ISO 18562-2,-3,-4

#### 11:30 - 12:00

SmartTrack: An Alternative Pathway to the Approval of Generic Respiratory Products

By Jan De Backer CEO at Fluidda, Lucas Silva Head of Analytical Development and Life Cycle

Management at Nanopharm, an Aptar Pharma Company

- » Presentation of SmartTrack approach to derisk and accelerate generic product development as a biowaiver for clinical end point studies. Introduction of the in vitro and in silico tools comprising SmartTrack platform under the umbrella of bioequivalence studies for generic orally inhaled products.
- » Presentation of SmartTrack in silico tools by Fluidda: Functional Respiratory Imagining and Rapid Deposition Analysis. Opportunities versus limitations and how, if combined together into the SmartTrack platform, they can make clinical trials shorter, faster and thus, more cost effective.
- » Presentation of SmartTrack realistic in vitro tools by Nanopharm and their application in a regulatory submission of a dry powder inhaler bioequivalent product.

#### 12:00 - 12:30

Inhaled New Modalities - from preclinical research to the clinic By Lena Ripa Director, Medicinal Chemistry at AstraZeneca

#### 12:30 - 13:00

Intertek Presentation (To be announced)

» Topic to be announced

### 13:00 - 14:00

**Business Lunch** 

#### 14:00 - 14:30

Interacting with FDA and Regulatory Bodies

By Deepika Lakhani Vice President of Regulatory & Quality at PAVmed Inc.

» Strategies and lessons of delivering and evaluating medical device submissions to FDA and other Regulatory bodies.

#### 14:30 - 15:00

Behavior design and connected devices. Simplifying the complex by identifying what matters

By **Søren Skov** Senior Human Factors Engineer at Roche

#### 15:00 - 15:30

The uncovered treasure of Post-Market Surveillance data

By Yvonne Limpens Managing Human Factors Specialist at Emergo by UL

» How to make the most of post-market data to develop safe and effective medical devices

#### 15:30 - 16:00

Inhaler technique errors impact the majority of patients - what strategies can change this?

By Mark Sanders Inventor and independent researcher

- » Since initial reports of inhaler technique difficulties in 1965 over 14,000 publication have explored the subject but the problems continue to exist.
- » Inhaler technique training is called for in GINA, GOLD and other reports and a plethora of tools exist to conduct inhaler training, and yet the problem persists...
- » This presentation reviews what has been done and the potential for new technologies in future.

#### 16:00 - 16:05

End of RESCON Europe & Chairperson Closing Remarks



#### **Package Name**

### REGISTRATION

Title: Title: Name: Name: Position: Position: E-mail: E-mail: Postcode: Company: Address: Phone: City: Gala Dinner Yes Nο VAT No.: Cocktail Reception Yes No Signature: Date: mm уууу

This booking is invalid without signature

Diogo Lino Ribeiro Project Director, Europe | Porto Office EM:diogo.ribeiro@epmgroup.org

PH:+351 915 239 640

Online

**Individual Registration** 

2-Days Online Access

Access to Live Talks

365 days access

on SocioPharma.com

#### Academic/NPO/Investor Individual or Group Registration

2-Days Access

Full Access to Exhibition Area

Full Access to all sessions

Coffee Breaks & Lunches

Pre-Cocktail Reception

**WOW Experience** 

Gala Dinner

Poster Presentation

365 days access on SocioPharma.com

### **Industry Package** Individual or Group Registration

2-Days Access

Full Access to Exhibition Area

Full Access to all sessions

Coffee Breaks & Lunches

Planet Cork Experience

Pre-Cocktail Reception

**WOW Experience** 

Gala Dinner

Poster Presentation

365 days access on SocioPharma.com

#### Premium Package Individual or Group Registration

2-Days Access Full Access to Exhibition Area Full Access to all sessions Coffee Breaks & Lunches Planet Cork Experience Pre-Cocktail Reception **WOW Experience** Gala Dinner Poster Presentation Hotel Included Airport Pick/Drop-Off Service

365 days access

#### **BOOK NOW BOOK NOW**

#### **BOOK NOW**

#### **BOOK NOW**

on SocioPharma.com

Till January 27th, 2023	Till March 31st, 2023	Till May 5th, 2023	After May 5th, 2023
295€	395€	495€	595€
955€	1095€	1195€	1295€
1595€	1795€	1995€	2195€
2395€	2595€	2795€	3095€
	295€ 955€ 1595€	295€ 395€ 955€ 1095€ 1595€ 1795€	295€       395€       495€         955€       1095€       1195€         1595€       1795€       1995€

<sup>\*</sup>The Rescon Summit is an exclusive limited seat event.

#### **Team Discounts**

3 Delegates	€3950	BOOK NOW
4 Delegates	€5200	BOOK NOW
5 Delegates	€6000	BOOK NOW

### **SPONSORSHIP PACKAGES**

#### **SILVER SPONSOR**

(VATINC.) €5200

- » 2-Days Access to the RESCON Summit
- » 2 delegates have admission
- » 30min Speaking Slot
- » Logo on website and main stage
- » Logo on Conferece Notebooks

- » Logo Display in all conference areas
- » Flyer/gifts into congress bags

#### **GOLD SPONSOR**

(VATINC.) €6000

- » 2-Days Access to the RESCON Summit
- » 3 delegates has admission
- » 6m2 exhibition space
- » 1/4 page Ad in conference program
- » Logo on website and main stage

- » Logo on Conferece Notebooks
- » Logo Display in all conference areas
- » Flyer/gifts into congress bags

(VATINC.) €8500

- » 2-Days Access to the RESCON Summit
- » 4 delegates has admission
- » 40min Speaking Slot
- 8m2 exhibition space
- » 1/2 page Ad in conference program
- » Logo on website and main stage

- » Logo on Conferece Notebooks
- » Logo Display in all conference areas
- » Flyer/gifts into congress bags
- » Gala Dinner Sponsor
- » Cocktail Reception Sponsor

#### Click bellow to register as sponsor

### **ONLINE REGISTRATION**

	Till January 27th, 2023	Till March 31st, 2023	Till May 5th, 2023	After May 5th, 2023
Silver Sponsorship	4000€	4200€	4800€	5200€
Gold Sponsorship	5000€	5200€	5500€	6000€
Diamond Sponsorship	7500€	7800€	8000€	8500€

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.


#### Cancellations

Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made

All Intellectual Property rights in all materials produced or distributed by EPM Group in connection with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.

<sup>\*</sup> Please send the signed form to this contact.



## **WORLD OF WINE**

This cultural district in the Gaia neighborhood on the opposite side of the Douro River from the Old Town is perfectly positioned for postcard-worthy views of Porto. From this vantage point, Porto's iconic building facades unfurl like a Madras patchwork of colors.


World of Wine is the perfect place to begin any visit to and through Portugal. Part museum, part dining, part shopping and part entertainment districts, this is a microcosm of all things Portuguese when it comes to food, drinks, art and history. Opened in mid-2020, but finally getting the global attention it deserves, World of Wine is a WOW experience. It actually goes by that acronym, and it's easy to see why.



## **PLANET CORK**

Portugal is by far the world's largest cork producing country, accounting for over 50% of global production, harvested from more than 730 hectares of forest.

Explaining and demonstrating how this natural product has changed our lives for the better, Planet Cork brings to life the incredible world of cork, from the ancient exploration of the cork oak to the most varied and avant-garde applications.



## **ANGEL'S SHARE**

In the Port wine city of Gaia, and housed in a refurbished wine warehouse, we're a short walk from the Douro River and several Port wine cellars. Enjoy our bar, with a view of Porto, a UNESCO World Heritage site, and 2,195 square meters of event space. Our Wellness Center offers treatments, an indoor pool, steam bath, sauna, and fitness facilities.



f in o rescon-europe.com







